Hepatocellular carcinoma: is surveillance cost effective?

door BRUIX, J, LLOVET, J
Gepubliceerd in 2001

Chronic intestinal pseudoobstruction and ophthalmoplegia in a patient with mitochondrial myopathy.

door Cervera, R, Bruix, J, Bayes, A, Blesa, R, Illa, I, Coll, J, Garcia-Puges, A M
Gepubliceerd in 1988

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

door Llovet, J M, Mas, X, Aponte, J J, Fuster, J, Navasa, M, Christensen, E, Rodés, J, Bruix, J
Gepubliceerd in 2002

Hepatitis G virus infection in chronic liver disease

door Guilera, M, Saiz, J, Lopez-Labrador, F, Olmedo, E, Ampurdanes, S, Forns, X, Bruix, J, Pares, A, Sanchez-Tapias, J, de Anta, M T J., Rodes, J
Gepubliceerd in 1998

Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series.

door Fuster, J, García-Valdecasas, J C, Grande, L, Tabet, J, Bruix, J, Anglada, T, Taurá, P, Lacy, A M, González, X, Vilana, R, Bru, C, Solé, M, Visa, J
Gepubliceerd in 1996

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

door Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J
Gepubliceerd in 2013